위원회 위원명단 - 대한내과학회

허헐성심질환 표준진료 권고안
15. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated
heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med
2006;354:1477-88.
16. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated
heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation
myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial
Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217-26.
17. Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention
in patients receiving enoxaparin or unfractionated heparin after fibrinolytic
therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25
trial. J Am Coll Cardiol 2007;49:2238-46.
18. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852
patients with acute myocardial infarction: randomised placebo-controlled trial.
Lancet 2005;366:1607-21.
19. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and
fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J
Med 2005;352:1179-89.
20. Scirica BM, Sabatine MS, Morrow DA, et al. The role of clopidogrel in early and
sustained arterial patency after fibrinolysis for ST-segment elevation myocardial
infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 2006;48:37-42.
21. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment
before percutaneous coronary intervention in patients with ST-elevation myocardial
infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;
294:1224-32.
22. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention
for patients with coronary and other atherosclerotic vascular disease: 2006
update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol
2006;47:2130-9.
23. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated
with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal
antiinflammatory drugs after acute myocardial infarction. Circulation 2006;
113:2906-13.
24. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with
acute ST-segment elevation myocardial infarction undergoing primary percutaneous
coronary intervention. Circulation 2009;119:3207-14.
25. Jeong HC, Ahn YK, Jeong MH, et al. Intensive pharmacologic treatment in patients
with acute non ST-segment elevation myocardial infarction who did not undergo
percutaneous coronary intervention. Circ J 2008;72:1403-9.
26. Kim HK, Jeong MH, Ahn Y, et al. A new risk score system for the assessment of
clinical outcomes in patients with non-ST-segment elevation myocardial infarction.
Int J Cardiol 2009.
27. Lee JH, Park HS, Chae SC, et al. Predictors of six-month major adverse cardiac
events in 30-day survivors after acute myocardial infarction (from the Korea Acute
Myocardial Infarction Registry). Am J Cardiol 2009;104:182-9.
28. Kwon TG, Bae JH, Jeong MH, et al. N-terminal pro-B-type natriuretic peptide is
associated with adverse short-term clinical outcomes in patients with acute ST-ele-
104